Non-invasive Prenatal Tests (NIPT) are new generation tests for screening and detection of chromosomal abnormalities during pregnancy. The NIPTs are performed on a maternal blood sample and evaluate the risk of the most common chromosomal alterations through the analysis of free fetal DNA circulating in the mother's blood.
Advanced maternal age increases the risk for the trisomies 21, 18, 13
In addition to genetic predisposition, advanced maternal age increases the risk of pregnancy at risk. This graph shows the correlation between the exponential growth of the risk of some trisomies and the maternal age.
During pregnancy, fragments of free fetal DNA circulate in the mother's blood. Fetal DNA is detectable starting from the 5th week of gestation and its concentration increases during the following weeks. The amount of fetal DNA present in the maternal bloodstream from the 11th week of gestation (12th week for twin pregnancies) is sufficient to perform the test and ensure accurate results.
Genechron provides the only non-invasive prenatal test of fetal DNA with CE mark (CE-IVD) for trisomies 21, 18 and 13 that can also detect the aneuploidies of all the chromosomes, different microdeletion syndromes and the sex of the unborn child.
It includes the screening of aneuploidy related to chromosomes 13, 18, 21 and sex determination (if required).
It includes the screening of aneuploidy related to chromosomes 13, 18, 21, X and Y, the detection of some microdelection syndromes and sex determination (if required).
It allows the detection of chromosomal numerical anomalies on the 22 pairs of autosomes and on the sex chromosomes (if fetal gender is required), the detection of microdelection syndromes (Cri-du-chat, DiGeorge, Prader-Willi / Angelman, 1p36) and fetal sex determination (if required).
For more information: